Renaissance Technologies's NVO Position Overview
Renaissance Technologies (via Renaissance Technologies LLC) currently holds 2.88 M shares of Novo Nordisk A/S (NVO) worth $159.92 M, representing 0.21% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Renaissance Technologies has maintained a long-term strategic position in NVO, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2017, adding 4.93 M shares. Largest reduction occurred in Q2 2017, reducing 5.75 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies's Novo Nordisk A/S (NVO) Holding Value Over Time
Track share changes against reported price movement
Quarterly Novo Nordisk A/S (NVO) Trades by Renaissance Technologies
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +27.95 M | Add 0.00% | 27.95 M | $15.50 |
| Q3 2013 | +3.42 M | Add 12.22% | 31.36 M | $16.92 |
| Q4 2013 | +1.28 M | Add 4.07% | 32.64 M | $18.48 |
| Q1 2014 | -477,400 | Reduce 1.46% | 32.16 M | $22.83 |
| Q2 2014 | +1.75 M | Add 5.43% | 33.91 M | $23.09 |
| Q3 2014 | -1.69 M | Reduce 5.00% | 32.21 M | $23.81 |
| Q4 2014 | -983,000 | Reduce 3.05% | 31.23 M | $21.16 |
| Q1 2015 | -2.2 M | Reduce 7.05% | 29.03 M | $26.69 |
| Q2 2015 | -853,200 | Reduce 2.94% | 28.17 M | $27.38 |
| Q3 2015 | -1.83 M | Reduce 6.50% | 26.34 M | $27.12 |
| Q4 2015 | -544,400 | Reduce 2.07% | 25.8 M | $29.04 |
| Q1 2016 | -246,200 | Reduce 0.95% | 25.55 M | $27.09 |
| Q2 2016 | +348,200 | Add 1.36% | 25.9 M | $26.89 |
| Q3 2016 | +3.41 M | Add 13.16% | 29.31 M | $20.79 |
| Q4 2016 | -1.42 M | Reduce 4.83% | 27.89 M | $17.93 |
| Q1 2017 | +4.93 M | Add 17.66% | 32.82 M | $17.14 |
| Q2 2017 | -5.75 M | Reduce 17.52% | 27.07 M | $21.44 |
| Q3 2017 | +1.65 M | Add 6.11% | 28.72 M | $24.08 |
| Q4 2017 | +2.74 M | Add 9.54% | 31.46 M | $26.84 |
| Q1 2018 | +2.72 M | Add 8.65% | 34.18 M | $24.63 |
| Q2 2018 | +4.1 M | Add 12.00% | 38.28 M | $23.06 |
| Q3 2018 | +1.05 M | Add 2.74% | 39.33 M | $23.57 |
| Q4 2018 | +2.16 M | Add 5.48% | 41.49 M | $23.03 |
| Q1 2019 | +1.2 M | Add 2.89% | 42.69 M | $26.16 |
| Q2 2019 | +2.35 M | Add 5.51% | 45.04 M | $25.52 |
| Q3 2019 | +4.53 M | Add 10.06% | 49.57 M | $25.85 |
| Q4 2019 | +2.86 M | Add 5.77% | 52.43 M | $28.94 |
| Q1 2020 | +3.29 M | Add 6.27% | 55.72 M | $30.10 |
| Q2 2020 | +1.7 M | Add 3.05% | 57.42 M | $32.74 |
| Q3 2020 | -1.18 M | Reduce 2.05% | 56.24 M | $34.71 |
| Q4 2020 | -2.56 M | Reduce 4.55% | 53.68 M | $34.93 |
| Q1 2021 | -3.99 M | Reduce 7.43% | 49.69 M | $33.71 |
| Q2 2021 | -1.33 M | Reduce 2.68% | 48.36 M | $41.88 |
| Q3 2021 | -5.08 M | Reduce 10.51% | 43.28 M | $48.01 |
| Q4 2021 | -5.05 M | Reduce 11.66% | 38.23 M | $56.00 |
| Q1 2022 | -1.47 M | Reduce 3.83% | 36.77 M | $55.53 |
| Q2 2022 | -1.71 M | Reduce 4.65% | 35.06 M | $55.71 |
| Q3 2022 | -4.44 M | Reduce 12.67% | 30.62 M | $49.82 |
| Q4 2022 | -5.41 M | Reduce 17.67% | 25.21 M | $0.07 |
| Q1 2023 | -3.6 M | Reduce 14.30% | 21.6 M | $0.08 |
| Q2 2023 | -2.86 M | Reduce 13.25% | 18.74 M | $0.08 |
| Q3 2023 | -2.51 M | Reduce 13.41% | 16.23 M | $90.94 |
| Q4 2023 | -2.38 M | Reduce 14.67% | 13.85 M | $103.45 |
| Q1 2024 | -3.06 M | Reduce 22.12% | 10.79 M | $128.40 |
| Q2 2024 | -1.62 M | Reduce 15.03% | 9.17 M | $142.74 |
| Q3 2024 | -976,059 | Reduce 10.65% | 8.19 M | $119.07 |
| Q4 2024 | +123,681 | Add 1.51% | 8.31 M | $86.02 |
| Q1 2025 | -1.49 M | Reduce 17.94% | 6.82 M | $69.44 |
| Q2 2025 | -1.88 M | Reduce 27.63% | 4.94 M | $69.02 |
| Q3 2025 | -2.05 M | Reduce 41.62% | 2.88 M | $55.49 |
Renaissance Technologies's Novo Nordisk A/S Investment FAQs
Renaissance Technologies first purchased Novo Nordisk A/S (NVO) in Q2 2013, acquiring 27,946,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies has held Novo Nordisk A/S (NVO) for 50 quarters since Q2 2013.
Renaissance Technologies's largest addition to Novo Nordisk A/S (NVO) was in Q2 2013, adding 27,946,000 shares worth $433.08 M.
According to the latest 13F filing for Q3 2025, Renaissance Technologies's firm, Renaissance Technologies LLC, owns 2,881,996 shares of Novo Nordisk A/S (NVO), valued at approximately $159.92 M.
As of the Q3 2025 filing, Novo Nordisk A/S (NVO) represents approximately 0.21% of Renaissance Technologies's publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies's peak holding in Novo Nordisk A/S (NVO) was 57,419,662 shares, as reported at the end of Q2 2020.